Cargando…
Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
Multimodal therapy is often used in oncology to overcome dosing limitations and chemoresistance. Recently, combination immunoradiotherapy has shown great promise in a select subset of patients with colorectal cancer (CRC). Furthermore, molecularly targeted agents delivered in tandem with immunothera...
Autores principales: | Landry, M.R., DuRoss, A.N., Neufeld, M.J., Hahn, L., Sahay, G., Luxenhofer, R., Sun, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689338/ https://www.ncbi.nlm.nih.gov/pubmed/33294836 http://dx.doi.org/10.1016/j.mtbio.2020.100082 |
Ejemplares similares
-
Development of a Pemetrexed/Folic Acid Nanoformulation:
Synthesis, Characterization, and Efficacy in a Murine Colorectal Cancer
Model
por: Rosch, Justin G., et al.
Publicado: (2020) -
In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018) -
Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells
por: Sargazi, Saman, et al.
Publicado: (2019) -
Isorhamnetin Exerts Antifibrotic Effects by Attenuating Platelet-Derived Growth Factor-BB-induced HSC-T6 Cells Activation via Suppressing PI3K-AKT Signaling Pathway
por: Rashidi, Mojtaba, et al.
Publicado: (2023) -
Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation
por: DuRoss, Allison N., et al.
Publicado: (2021)